{"entity":{"id":"imaging-core-labs","kind":"technology","name":"Imaging core labs and central review","aka":[],"tldr":"Independent radiologists who re-read every scan in a trial the same way, so response rates mean the same thing across hospitals.","summary":"Blinded independent central review (BICR) applies RECIST, iRECIST, Lugano, or PCWG3 criteria consistently across sites and is expected by regulators for PFS and ORR endpoints. Vendors: Calyx (formerly Parexel Informatics), ICON Medical Imaging, Clario (Bioclinica + ERT), Median Technologies, WCG Imaging, and Radiology Partners' research arm. AI-assisted lesion tracking and quantitative imaging biomarkers are entering the workflow.","status":"standard-of-care","asOf":"2026-09-08","links":[{"label":"FDA guidance: clinical trial imaging endpoint process standards","url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-imaging-endpoint-process-standards-guidance-industry"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["imaging"],"technologies":["ct","pet-ct","contract-research-organisations"],"targets":[],"drugs":[],"companies":["calyx","icon-plc","clario"],"institutions":[],"pathways":[],"terms":["recist","bicr"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"principle":"De-identified DICOM images uploaded to a central platform; two readers plus adjudicator score per protocol charter; discrepancy rates and read variability are tracked.","strengths":["Endpoint integrity","Regulatory acceptance"],"limitations":["Cost and turnaround","Discordance with local read (~30% of progression calls)"]},"route":"/technologies/imaging-core-labs/","neighbours":{"section":[{"id":"imaging","kind":"section","name":"Imaging","route":"/fronts/imaging/"}],"technology":[{"id":"contract-research-organisations","kind":"technology","name":"Contract research organisations (CROs)","route":"/technologies/contract-research-organisations/"},{"id":"ct","kind":"technology","name":"CT (computed tomography)","route":"/technologies/ct/"},{"id":"pet-ct","kind":"technology","name":"PET/CT","route":"/technologies/pet-ct/"},{"id":"quantitative-imaging-biomarkers","kind":"technology","name":"Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC)","route":"/technologies/quantitative-imaging-biomarkers/"}],"company":[{"id":"calyx","kind":"company","name":"Calyx","route":"/companies/calyx/"},{"id":"clario","kind":"company","name":"Clario","route":"/companies/clario/"},{"id":"icon-plc","kind":"company","name":"ICON plc","route":"/companies/icon-plc/"},{"id":"medpace","kind":"company","name":"Medpace","route":"/companies/medpace/"}],"term":[{"id":"bicr","kind":"term","name":"Blinded independent central review (BICR)","route":"/terms/bicr/"},{"id":"recist","kind":"term","name":"RECIST","route":"/terms/recist/"}],"roadmap":[{"id":"trial-modernisation-roadmap","kind":"roadmap","name":"Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on","route":"/roadmaps/trial-modernisation-roadmap/"}]}}